From Promise to Progress: More Durable Treatments for Neovascular Retinal Diseases - nAMD Interactive Data Deep Dive

From Promise to Progress: More Durable Treatments for Neovascular Retinal Diseases - nAMD Interactive Data Deep Dive is organized by Paradigm Medical Communications, LLC.

Release Date: June 2, 2022
Expiration Date: June 2, 2023

Program Overview:
This engaging infographic activity will take learners on an interactive, multimedia journey through the pivotal phase 3 trials that led to the recent FDA approvals of 2 exciting new therapies for the treatment of neovascular retinal diseases—faricimab, a first-in-class bispecific antibody indicated for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), and the ranibizumab port delivery system (PDS), a first-of-its-kind sustained anti-vascular endothelial growth factor delivery device indicated for nAMD.

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Articulate clinical trial designs of recently available novel therapies that are indicated for the treatment of neovascular retinal diseases
• Summarize safety and efficacy data for recently available novel treatments for neovascular retinal diseases.